Georgia's Online Cancer Information Center

Find A Treatment Site

Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center

The Curtis and Elizabeth Anderson Cancer Institute (ACI) at Memorial University Medical Center, is a cancer center in Savannah, Georgia. Memorial Health is accredited by the Commission on Cancer of the American College of Surgeons as a Teaching Hospital Cancer Program. The center is a recipient of the Georgia Cancer Coalition Distinguished Cancer Scholars Award, which supports leaders who are engaged in the most promising areas of cancer research. Memorial Health is a member of the Georgia CORE Research Network, a statewide network of academic and community-based oncologists and researchers and a member of the Georgia CORE Gynecologic Oncology Group Consortium. The center consists of 32 physicians, including two radiation oncologists. Memorial Health offers a state-of-the-art research laboratory, leading-edge technology and compassionate support programs. They offer the following services: community support groups, educational programs, insurance assistance, resource room, oncology interdisciplinary care, coordination team, oncology social workers, patient advocacy, support line, wellness services, spiritual care and pediatric services.

Treatment Sites in Georgia

Clinical Trials in Georgia

A Study of Combination Chemotherapy for Patients with Newly Diagnosed DAWT and Relapsed FHWT
Cancer Type: Brain Tumor, Unknown Primary, Wilms Tumor

A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Cancer Type: Hematopoietic Malignancies, Leukemia, Unknown Primary

A Study to Compare Standard Chemotherapy to Therapy with CPX-351 and/or Gilteritinib for Patients with Newly Diagnosed AML with or without FLT3 Mutations
Cancer Type: Leukemia

A Study to Investigate Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed B-Lymphoblastic Leukemia
Cancer Type: Leukemia

Dabrafenib Combined with Trametinib after Radiation Therapy in Treating Patients with Newly-Diagnosed High-Grade Glioma
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor

Imatinib Mesylate and Combination Chemotherapy in Treating Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Cancer Type: Leukemia

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
Cancer Type: Hodgkin Lymphoma

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients with High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Cancer Type: Leukemia, Testicular Cancer

Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Cancer Type: Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Intraoperative Radiation Therapy in Treating Patients with Breast Cancer Undergoing Breast-Conserving Surgery
Cancer Type: Breast Cancer

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab with or without Eflornithine in Treating Patients with Relapsed or Refractory Neuroblastoma
Cancer Type: Neuroblastoma

Pilot Study of Neuropsychological and Behavioral Assessment in Children With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)
Cancer Type: Brain Tumor

Radiation Therapy with or without Chemotherapy in Patients with Stage I-IIA Cervical Cancer Who Previously Underwent Surgery
Cancer Type: Cervical Cancer

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients with Newly Diagnosed WNT-Driven Medulloblastoma
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary

Research Study of Clinical, Genetic, and Biological Factors as Prognostic Values in Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Cancer Type: Neuroblastoma

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients with Non-high Risk Neuroblastoma
Cancer Type: Neuroblastoma, Neurologocal Tumor

Samotolisib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders with Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor, Hematopoietic Malignancies, Liver Cancer / Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor

Study of Renal Tumors in Pediatric Patients
Cancer Type: Kidney Cancer

Sublobar Resection or Stereotactic Ablative Radiotherapy in Treating Patients with Stage I Non-small Cell Lung Cancer, The STABLE-MATES Trial
Cancer Type: Lung Cancer, Unknown Primary

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Bladder Cancer, Brain & Spinal Cord Tumor, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Plasma cell neoplasm, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Thyroid Cancer, Unknown Primary, Uterine Cancer

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor

Tazemetostat in Treating Patients with Recurrent Ovarian or Endometrial Cancer
Cancer Type: Ovarian Cancer, Uterine Cancer

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People with High-Risk Neuroblastoma (NBL)
Cancer Type: Neuroblastoma, Neurologocal Tumor

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
Cancer Type: Lung Cancer

Testing Whether Avoiding the Hippocampus During Whole-Brain Radiation Therapy Prevents Cognitive Side Effects in Patients with Small Cell Lung Cancer
Cancer Type: Lung Cancer

Use of a Pre-surgical Toolkit in Improving Surgical Care and Outcomes in Older Patients with Cancer
Cancer Type: Solid Tumor
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.